Aortic Stenosis: Unlocking the Secrets of Inflammation for Better Heart Health
"Discover how inflammation in aortic stenosis is shaping the future of heart disease biomarkers and what it means for you."
Aortic stenosis (AS), a common heart valve disease, affects many, especially in Western countries. For years, treatment was limited, but the introduction of transcatheter aortic valve replacement (TAVR) has changed the game. TAVR offers a less invasive option for those at high risk during traditional surgery, marking a significant advancement in cardiac care.
Despite TAVR's success, there are still gaps in our understanding of AS. We don’t fully know what causes aortic valve degeneration, making it difficult to predict the course of the disease or identify who is most at risk. This lack of clarity has spurred intense research into biomarkers that can help us better understand and manage AS.
Like vascular atherosclerosis, AS involves chronic inflammation of the heart valve. While there's plenty of research on inflammation and biomarkers in atherosclerosis, there's less information about their role in AS. Scientists are now exploring how inflammatory biomarkers and other circulating molecules affect AS pathophysiology, seeking new ways to diagnose and treat this condition.
Prevalence, Severity, and Inflammation
In the United States, aortic stenosis is the second most common valvular lesion, affecting approximately 5% of people aged 65 and older. Reported prevalence rises from 0.2% among adults aged 50–59 to 9.8% among those aged 80–89. Research published May 1, 2025, indicates that specific inflammatory biomarker pathways may contribute to aortic stenosis, although further validation is needed before cytokine-targeted pharmacological or lifestyle interventions can be assessed as treatments.
Assessment and Earlier Intervention
Accurate assessment of aortic stenosis is essential for prognosis and treatment decisions. Echocardiography and computed tomography are among the non-invasive diagnostic methods discussed in biomechanical assessments, each with advantages and limitations. The 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines challenge symptom-driven watchful waiting by supporting earlier treatment for many patients with asymptomatic severe aortic stenosis.
From Surgical Replacement to Modern Understanding
In 1663, French physician Lazare Rivière provided an early description of calcific aortic stenosis, identifying left ventricular hypertrophy and obstructive masses in an autopsy report. During the 1960s, open-heart surgery made aortic valve replacement possible, extending and improving the lives of patients with a previously debilitating and nearly always fatal condition. Modern accounts also describe a shift from rheumatic fever as the primary cause toward an active inflammatory process with features resembling atherosclerosis, while the 1968 natural-history work of John Ross Jr and Eugene Braunwald became an influential milestone in understanding the disease.
How Inflammation and Growth Factors Impact Heart Remodeling in Aortic Stenosis
Left ventricular hypertrophy (LVH), or the thickening of the heart's main pumping chamber, is a major risk factor for cardiovascular events in AS. However, the severity of LVH varies among AS patients, and the degree of AS only partially accounts for this variation. This has led researchers to investigate the role of inflammatory cytokines and growth factors in explaining why LVH differs from person to person. Understanding these factors could provide insights into cardiac remodeling in AS.
- Key Findings: The study revealed that while many patients had normal left ventricular ejection fraction (LVEF) at the start, most showed abnormal global longitudinal strain (GLS), diastolic dysfunction (elevated mitral E/e' ratio), and increased LV mass index (LVMI).
- Cytokine Patterns: The analysis uncovered a unique pattern of association between circulating molecules, increases in LVMI, and decreases in GLS.
- HGF and LVMI: Higher baseline LVMI was strongly linked to elevated levels of hepatocyte growth factor (HGF). Though higher HGF levels were also associated with low GLS values, vascular endothelial growth factor (VEGF)-D was strongly tied to GLS reduction.
- Canonical Growth Factors: Despite the involvement of other cytokines, the most significant associations were found with two well-known growth factors that profoundly affect how heart muscle cells respond to stress.
Inflammatory Biomarkers and Myocardial Fibrosis
Recent research has examined inflammatory biomarkers in relation to aortic stenosis and myocardial fibrosis. In the cited study, no significant relationship was observed between the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, and myocardial fibrosis assessed by cardiac magnetic resonance. This finding indicates that these blood-based indices did not demonstrate the reported association with myocardial fibrosis in that analysis.
Evidence Gaps in Biomarker-Led Care
Inflammatory and imaging biomarkers remain promising but are not yet fully established for routine clinical decision-making. A review of novel biomarkers and advanced cardiac imaging states that randomized clinical trials are needed to define their utility in daily practice. Other clinical discussions emphasize that diagnosis and staging, together with patient risk profiles, continue to guide treatment decisions, while research has also described increased cardiac-cell stiffness and reduced soluble guanylyl cyclase-cGMP-PKG signaling in heart-failure models and human left-ventricular biopsies from patients with HFpEF.
Inflammation, Age, and Metabolic Burden
Aortic stenosis is described as the most common type of valvular heart disease in developed countries, with prevalence increasing dramatically with age. In the United States, moderate or severe disease ranges from 0.02% to 0.1% among people aged 18–44 and from 2.8% to 4.6% among those aged 75 or older. Research on calcific aortic valve disease identifies inflammation, fibrosis, and impaired leaflet motion as early signs, while obesity is described as promoting systemic inflammation and adding to the inflammatory burden of chronic comorbidities.
The Future of Biomarkers in Aortic Stenosis
In conclusion, Kim et al.'s study offers a comprehensive overview of inflammatory cytokines linked to LV function in AS and functional recovery after TAVR. By mapping the inflammatory network in AS, this research provides potential sources for clinically valuable biomarkers. Further research, including a careful assessment of the 'chronic inflammatory state' in AS, should continue to refine our understanding and treatment of this condition.
Inflammation and Lipoprotein(a) Risk
A 2026 cohort study among UK Biobank participants is assessing whether inflammatory biomarkers modify lipoprotein(a)-associated risk for coronary artery disease and aortic stenosis. The study focuses on a primary-prevention population, linking inflammation and lipoprotein(a) to risk assessment rather than establishing a treatment. Its findings may help clarify how inflammatory status relates to lipoprotein(a)-associated cardiovascular risk.
Breaking the Mechanical-Inflammatory Cycle
Future research is examining the proposed vicious cycle between mechanical stress and inflammation in calcific aortic valve disease. One research framework describes an initiation-perpetuation hypothesis for inflammation in aortic stenosis pathophysiology. Alongside this mechanistic work, biomarker research, potential advances in transcatheter aortic valve replacement, and personalized care are being explored, while the global aortic stenosis market is projected to grow from USD 11.26 billion in 2026 to USD 22.94 billion in 2033, a reported compound annual growth rate of 10.7%.
When Standard Imaging Misses the Gradient
A 2024 case report describes critical aortic stenosis diagnosed using an approach that addressed limitations of standard Doppler echocardiography. Aortic stenosis severity is typically evaluated with Doppler echocardiography, but measurements from the apical window may underestimate the true gradient when blood flow is misaligned with the ultrasound beam. The report notes that the gradient may therefore be better evaluated from another acoustic window.